Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma

(2017) Henrik Watz et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Smoking and drug interactions

(2016) Catherine Lucas et al.   Australian Prescriber

The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions

(2015) Stipo Jurcevic et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Therapeutic implications of ‘neutrophilic asthma’

(2015) Parameswaran Nair et al.   CURRENT OPINION IN PULMONARY MEDICINE

A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis

(2015) Anthony De Soyza et al.   EUROPEAN RESPIRATORY JOURNAL

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD

(2015) A.M. Kirsten et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Neutrophils in chronic inflammatory airway diseases: can we target them and how?

(2010) Y. Gernez et al.   EUROPEAN RESPIRATORY JOURNAL